Neutralizing power of blood and nasal antibodies

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This monocentric, longitudinal descriptive study will follow adults who receive SARS-CoV-2 or MPXV vaccines or monoclonal antibodies and collect blood and optional nasal swab samples up to 60 months. Laboratory assays will measure neutralizing activity in serum and nasal secretions at multiple time points to map the durability of the humoral response. The protocol is observational and does not change clinical care—samples are collected around vaccination or treatment events. Data will be used to describe how neutralizing power changes over time and in relation to different vaccines or monoclonal products.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Adults (≥18 years)
* Patients receiving or scheduled to receive anti-SARS-CoV-2 and/or anti-MPXV vaccines or monoclonal antibodies
* Patients have provided written informed consent

Exclusion Criteria:

* Persons under guardianship or curatorship
* Persons under legal protection,
* Persons persons deprived of liberty
* Persons not affiliated to a social security scheme
* Pregnant or breastfeeding women

Where it's running

• CHU Orléans
  Orléans, France Recruiting

Study contacts

• Principal investigator: Thierry PRAZUCK, Dr — CHU Orléans
• Study coordinator: Thierry PRAZUCK, Dr
• Email: thierry.prazuck@chu-orleans.fr
• Phone: 0238229593

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Comparative Immunogenicity of Respiratory Virus Vaccines (CIRV2) in Adults

  This study tests and compares the immune responses and tolerability of the latest COVID-19 vaccines from Novavax and Pfizer/BioNTech in adults at risk for severe COVID-19.

  Recruiting Phase 4 Henry M. Jackson Foundation for the Advancement of Military Medicine · Bethesda, Maryland · NCT07287137

• RSV vaccine safety and immune response in lung transplant patients vs. healthy adults

  This study tests how well the RSV vaccine works and how safe it is in people who have had a lung transplant compared with healthy adults.

  Recruiting Phase 4 Seoul National University Hospital · Seoul, Jongno-Gu · NCT07895394

• Omicron-based COVID-19 vaccine with Matrix-M given as a single dose in older adults and high-risk individuals

  A single-dose Omicron-subvariant vaccine with Matrix-M is tested to see if it is safe and can induce an immune response in adults 65+ and in younger adults with conditions that raise the risk of severe COVID-19, who were previously vaccinated.

  Recruiting at 20 sites Phase 4 Sanofi · Fair Oaks, California and 19 other locations · NCT07861542

• Secutrelvir for nonhospitalized COVID-19 in teens and adults

  This study tests whether secutrelvir can help nonhospitalized people with COVID-19 see faster symptom relief compared with a placebo.

  Recruiting Phase 3 Shionogi Inc. · Multiple Locations · NCT07746544

• Sleep and Teens’ Immune Response to a Meningococcal Vaccine

  This study checks if 11- to 12-year-olds’ sleep habits affect how well their vaccine for meningococcal disease works.

  Recruiting Children's Hospital Medical Center, Cincinnati · Cincinnati, Ohio · NCT07636525

• Virological Monitoring of Seasonal Respiratory Infections in France

  This project tests how often common respiratory viruses show up in patients seen by primary care doctors in metropolitan France during the fall and winter.

  Recruiting Institut National de la Santé Et de la Recherche Médicale, France · Paris · NCT07599449

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.